|Mr. Karolis Rosickas||Chief Exec. Officer||526.15k||N/A||N/A|
|Prof. Graham Vesey Ph.D.||Chief Scientific Officer & Exec. Director||120.87k||N/A||1965|
|Dr. Charlotte Morgan Ph.D.||Head of R&D||N/A||N/A||N/A|
|Ling Leung Hang||Company Sec.||N/A||N/A||N/A|
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was incorporated in 2007 and is headquartered in Paddington, Australia.
Regeneus Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.